Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)
Trial details
- Registry ID
- NCT05397470
- Drugs studied
- Losmapimod
TrialRedline tracks 6 clinical trials sponsored by Fulcrum Therapeutics: 2 Phase 3, 4 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)NCT05397470 | Losmapimod | Terminated | 2024-11-19Actual |
| Losmapimod Safety and Efficacy in COVID-19NCT04511819 | Losmapimod oral tablet | Terminated | 2021-03-31Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)NCT04003974 | Losmapimod oral tablet | Completed | 2021-01-28Actual |
| Open-Label Extension Study to Pioneer Study 6058-SCD-101NCT07401823 | Pociredir | Terminated | 2026-06-04Actual |
| Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)NCT04264442 | Losmapimod | Terminated | 2024-11-07Actual |
| Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With ExtensionNCT04004000 | Losmapimod | Terminated | 2024-10-31Actual |
Names as written in the registry records.
NCT07401823 · Fulcrum Therapeutics
Before: Estimated. After: Actual.
Before: 50 participants (planned). After: 1 participants (actual).
Before: Estimated. After: Actual.
Before: 4 Feb 2030. After: 4 Jun 2026.
Before: Enrolling by invitation. After: Terminated.
NCT07401823 · Fulcrum Therapeutics
Before: Not yet recruiting. After: Enrolling by invitation.
NCT04004000 · Fulcrum Therapeutics
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Main Study and Extension Study - Treatment-Emergent Adverse Events. After: Measure: Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs Measure: Number of Participants With Clinically Significant Changes in Chemistry Parameters Measure: Number of Participants With Clinically Significant Changes in Hematology Parameters Measure: Number of Participants With Clinically Significant Changes in Serum Coagulation Parameters.